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Castleman’s disease is a benign lymphoproliferative disease characterised by hyperplasia of lymphoid follicles. It can
affect any lymph nodes in the body. Here we describe a caucasian patient who presented with six months history
of shortness of breath with CT scan confirming an 8 cm segment of consolidated lung in left hilum. PET scan
revealed a mass measuring 68x80x55 mm extending from the left hilum out into the left upper lobe containing
area of calcification with SUV max 4.8. The differential diagnosis included atypical sequestration, hamartoma and
primary lung malignancy. The patient underwent left video assisted enucleation of the lesion. The histology
confirmed the diagnosis of Castleman’s disease.
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Castleman’s disease is known as giant or angiofollicular
lymph node hyperplasia, lymphoid hamartoma, or angio-
follicular lymph node hyperplasia. It is named after Dr
Benjamin Castleman who described this disease in 1954
from Massachusetts General Hospital [1]. The aetiology
of the disease is unknown. It can develop in a single
lymph node or series of lymph nodes. Castleman’s dis-
ease has been described as two clinical identities (i) uni-
centric/solitary/localised that involves single site for
which removal of lymph node is curative and (ii) multi-
centric or systemic form of Castleman’s disease, which is
associated with involvement of multiple lymph nodes
and presents with systemic symptoms. Treatment of the
systemic form involves corticosteroid; systemic chemo-
therapy or radiotherapy can be considered for disease
control. This report presents a case of hyaline vascular
variant of Castleman’s disease which was treated with
left video assisted thoracoscopic surgery.Case presentation
A 24 year old non-smoking caucasian lady presented with
six months history of shortness of breath and productive
cough, which did not improve with antibiotics. Clinical
examination identified a bilateral significant wheeze. Rou-
tine haematological and biochemistry tests were normal.
Her FEV1 was 1.6 l (55% predicted) and FVC 3.04 l (92%* Correspondence: dmcanupama@hotmail.com
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unless otherwise stated.predicted). CT revealed an 8 cm well demarcated segment
of consolidated lung in the left hilum (Figure 1). On PET
scan (Figure 2) it was hypermetabolic returning an SUV
max 4.8. The radiological appearance was suggestive of se-
questration or hamartoma. A CT-guided biopsy was inde-
terminate and she was therefore referred for surgery.
During VATS, the lesion was identified in the left hilum in
a haemorrhagic capsule.
The lesion was partially enucleated; a feeding bron-
chus, artery and vein were ligated. The histology from
the left upper lobe mass revealed hyaline vascular vari-
ant of Castleman’s disease. Postoperative recovery was
uneventful.Discussion
In this case, Castleman’s disease presented as a mass lo-
cated in the left lung near to the hilum. Attempts at a
preoperative diagnosis were unhelpful. CT guided biopsy
was inconclusive. She was therefore referred for surgery
for diagnostic and therapeutic reasons.
Castleman’s disease may affect anyone from adolescent to
seventh decade with equal sex distribution. It is reported to
involve any lymph nodes in the body such as cervical (42%),
mediastinal (31%), intraabdominal (18%), and retroperiton-
eal (5%). Only 5% can involve extranodal lymph node [2].
Unicentric Castleman’s disease presents with a slow growing
mass, while multicentric variant manifests as fever, malaise,
weight loss and generalised lymphadenopathy.
Histologically three types are identified - hyaline vas-
cular variety (90%) and plasma cells type (8-9%) andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 CT scan of the Castleman’s disease.
Barua et al. Journal of Cardiothoracic Surgery 2014, 19:170 Page 2 of 3
http://www.cardiothoracicsurgery.org/content/19/1/170intermediary mixed type (1-2%) [3]. The hyaline vascular
type is identified by dense capillary proliferation and
lymphocyte –predominant infiltrate surrounding a small
germinal centre. The presence of sheets of mature plasma
cells surrounding the normal-large germinal centre is the
diagnostic feature of plasma cell variant.
Hyaline variant is generally asymptomatic and may be
associated with iron deficiency anaemia and throm-
bocytopenia whereas the plasma cell verity is associated
with infection, lymphoma, immunodeficiency, Kaposi’s
sarcoma, non-Hodgkin lymphoma, glomeruloid haem-
angioma, plasmacytoma, malignancies of colon, kidney
and thyroid [4,5]. POEMS- polyneoropathy, organome-
galy, endocrinopathy, monoclonal gammopathy and
skin changes are also manifestations of plasma cell type
Casleman’s disease [5]. Danon et al. suggests that hyline
vascular variant may originate from antigen stimulus
such as abnormal plasmacytoid monocytes and plasma
cell variant could be a response from chronic infection [2].
Diagnosis of localised Castleman’s disease may be difficult
in the presence of very few symptoms. On chest radio-
graph, it may appear as an incidental rounded solitaryFigure 2 PET scan of the Castleman’s disease.mediastinal or hilar mass with a differential diagnosis that
includes thymoma, lymphoma, neurogenic tumor or bron-
chial adenoma. In contrast, multicentric Castleman's disease
may appear as bilateral hilar and mediastinal enlargement or
diffuse reticulonodular pulmonary infiltrations [6].
CT scanning reveals three morphologic patterns of uni-
centric thoracic Castleman’s disease: a solitary, noninvasive
mass (50% of cases); a dominant mass with involvement of
contiguous structures (40% of cases); or a matted lymph-
adenopathy confined to a single mediastinal compartment
(10% of cases) [6]. Hypervascularity of the lesion may reveal
homogeneously intense contrast enhancement in CT. 5–
10% of Castleman's disease demonstrated intralesional calci-
fications, typically being discrete, coarse, or distinctive with
an “arborizing” pattern in enhanced CT [6]. For thoracic
Castleman's disease MRI can be used as it demonstrates the
extent of the tumour, clarifies its relationship to the bronch-
ovascular structures and shows the feeding vessels. Similar
to other inflammatory disease, Castleman’s disease shows
mild to moderate FDG uptake in PET scan. Histological
diagnosis before surgical removal can be done by CT guided
biopsy, EUS and EBUS if the anatomical position permits.
Surgical resection is diagnostic and curative for
unicentric Castleman’s disease. As described before,
corticosteroid therapy, chemotherapy and monoclonal anti-
body treatment are suitable for multicentric Castleman’s
disease. Surgical excision may not be easy in unicentric
hyaline vascular type due to high vascularity. It may be
associated with massive haemorrhage at excision and pneu-
monectomy has been reported for massive bleeding [7].
Embolization of the feeding artery before surgery can be
considered to prevent intraoperative bleeding. Complete
surgical resection is the gold standard treatment in uni-
centric Castleman’s disease and is also required for
complete recovery in the majority of cases. The prognosis
is good after surgical excision in unicentric Castleman’s dis-
ease, and 5-year survival is 100% [8]. On the contrary, mul-
ticentric Castleman’s disease has a poor prognosis with a
median survival of thirty months. Nevertheless, splenec-
tomy with systemic chemotherapy and steroids can im-
prove the prognosis in multicentric Castleman’s disease [9].
Although Castleman’s disease is classed as a benign disease,
long term follow up is required as recurrence can happen
as late as eight years after the diagnosis of the disease [8].Conclusion
This is a rare case report of Castleman's disease. It is
important to remember Castleman's disease as a differ-
ential diagnosis in benign lung parenchymal lesion. In
this case the patient was treated by VATS enucleation of
the lesion avoiding unnecessary lung resection. To our
knowledge, this is the first lesion which was removed by
keyhole surgery.
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